BioCentury
ARTICLE | Company News

Micromet, AstraZeneca deal

November 9, 2009 8:00 AM UTC

Micromet bought out all remaining rights to blinatumomab (MT103) and all other bispecific T cell engager (BiTE) antibodies for hematological cancers from AstraZeneca's MedImmune LLC subsidiary, endin...